Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction: Results from the cooperative cardiovascular project

Stroke

Volumn 31, Issue 8, 2000, Pages 1802-1811

  Brass, Lawrence M ^a,b,c,d   Lichtman, Judith H ^a,c   Wang, Yun ^d   Gurwitz, Jerry H ^e   Radford, Martha J ^a,d   Krumholz, Harlan M ^a,c,d  

^a YALE NEW HAVEN HOSPITAL   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d QUALIDIGM   (United States)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Intracranial hemorrhage; Myocardial infarction; Risk factors; Thrombolytic therapy

Indexed keywords

ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; AGED; ANTICOAGULANT THERAPY; ARTICLE; BRAIN HEMORRHAGE; COHORT ANALYSIS; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; UNITED STATES;

EID: 0033862472     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.31.8.1802     Document Type: Article

References (65)

1. ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)
2. Guidelines for the early management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on the Assessment of Diagnostic and Therapeutic Cardiovascular Procedures
3. Thrombolytic therapy for eligible elderly patients with acute myocardial infarction
4. Thrombolytic therapy for elderly patients
5. Coronary thrombolysis for the elderly: Is clinical practice really lagging behind evidence of benefit?
6. Ischemic stroke and intracranial hemorrhage following thrombolytic therapy for acute myocardial infarction: A risk-benefit analysis
7. The risk of intracranial hemorrhage after tPA treatment for acute myocardial infarction
8. Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction: A report from the Second National Registry of Myocardial Infarction (NRMI-2)
9. Improving the quality of care for Medicare patients with acute myocardial infarction: Results from the Cooperative Cardiovascular Project
10. National use and effectiveness of β-blockers for the treatment of elderly patients after acute myocardial infarction
11. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction
12. Comprehensive reliability assessment and comparison of quality indicators and their components
13. Risk factors for intracranial hemorrhage in outpatients taking warfarin
14. Bleeding during antithrombotic therapy in patients with atrial fibrillation
15. Current issues concerning thrombolytic therapy for acute myocardial infarction
16. The fifth ACCP Consensus Conference on Antithrombotic Therapy: Coronary thrombolysis
17. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients
18. Effectiveness of intravenous thrombolytic therapy in acute myocardial infarction
19. ISIS-3: A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction
20. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study
21. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction
22. Intracranial bleeding, fibrinolysis, and anticoagulation
23. Beyond randomized clinical trials: Applying clinical experience in the treatment of patients with coronary artery disease
24. Intracranial hemorrhage in association with thrombolytic therapy: Incidence and clinical predictive factors
25. The exclusion of the elderly and women from clinical trials in acute myocardial infarction
26. Intravenous tissue plasminogen activator and size of infarct, left ventricular function and survival in acute myocardial infarction
27. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: No additional benefit from immediate percutaneous coronary angioplasty
28. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) phase II trial
29. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction
30. Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction
31. A randomised controlled trial of intravenous heparin in acute myocardial infarction
32. Accelerated plasminogen activator dose regimens for coronary thrombolysis: The TAMI-7 Study Group
33. The Greater Cincinnati/Northern Kentucky Stroke Study: Preliminary first-ever and total incidence rates of stroke among blacks
34. Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction: The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators
35. Hypertension and subclinical carotid artery atherosclerosis in blacks and whites: The Atherosclerosis Risk in Communities Study: ARIC Investigators
36. Comparison of in-hospital outcome in men versus women treated by either thrombolytic therapy or primary coronary angioplasty for acute myocardial infarction
37. Stroke after thrombolysis: Mortality and functional outcomes in the GUSTO-I trial: Global Use of Strategies to Open Occluded Coronary Arteries
38. The risk of stroke in patients with acute myocardial infarction after thrombolysis and antithrombotic treatment
39. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy: GUSTO-I Investigators
40. After correcting for worse baseline characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity as men except for a higher incidence of hemorrhagic stroke
41. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
42. Individual risk assessment for intracranial hemorrhage during thrombolytic therapy
43. Thrombolysis-related intracranial hemorrhage: A radiographic analysis of 244 cases from the GUSTO-1 trial with clinical correlation: Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries
44. Treatment and outcome of patients with acute myocardial infarction and prior cerebrovascular events in the thrombolytic era: The Israeli Thrombolytic National Survey
45. Presenting pulse pressure predicts thrombolytic therapy-related intracranial hemorrhage: Thrombolytic Predictive Instrument (TPI) Project results
46. Tissue plasminogen activator for acute ischemic stroke
47. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: The European Cooperative Acute Stroke Study (ECASS)
48. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)
49. Dementia as a predictor of adverse outcomes following stroke: An evaluation of diagnostic methods
50. Intracerebral hemorrhage related to cerebral amyloid angiopathy and t-PA treatment
51. Patient-specific predictions of outcomes in myocardial infarction for real-time emergency use: A thrombolytic predictive instrument
52. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction
53. Patient preferences for thrombolytic therapy in acute myocardial infarction
54. Incorporating patient preferences into medical decisions
55. Patient preferences for stroke outcomes
56. An approach to evaluating thrombolytic therapy in acute myocardial infarction: The 'unsatisfactory outcome' end point
57. Efficacy and cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction
58. Observational studies in neuroepidemiology: Methodological issues
59. Discussing hidden bias in observational studies
60. Quality of care for Medicare patients with acute myocardial infarction: A four-state pilot project from the cooperative cardiovascular project
61. Geographic variation in the treatment of acute myocardial infarction: The Cooperative Cardiovascular Project
62. Inaccuracy of the International Classification of Diseases (ICD-9-CM) in identifying the diagnosis of ischemic cerebrovascular disease
63. Interobserver agreement in the diagnosis of stroke type
64. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction